Richard Kendall

5.1k total citations · 1 hit paper
43 papers, 3.0k citations indexed

About

Richard Kendall is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Richard Kendall has authored 43 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 18 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Richard Kendall's work include Cancer, Hypoxia, and Metabolism (9 papers), Microtubule and mitosis dynamics (8 papers) and Cancer Treatment and Pharmacology (8 papers). Richard Kendall is often cited by papers focused on Cancer, Hypoxia, and Metabolism (9 papers), Microtubule and mitosis dynamics (8 papers) and Cancer Treatment and Pharmacology (8 papers). Richard Kendall collaborates with scholars based in United States, Sweden and Germany. Richard Kendall's co-authors include Kenneth A. Thomas, Guan Wang, Robert Radinsky, Xianzhi Mao, William R. Huckle, Angela Coxon, Teresa L. Burgess, Ruth Z. Rutledge, Randall W. Hungate and Andrew J. Tebben and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Richard Kendall

42 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR

1996 597 citations Richard Kendall, Guan Wang et al. Biochemical and Biophysical Research Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Kendall United States	24	1.8k	837	476	324	315	43	3.0k
Randall Schreck United States	9	1.5k 0.8×	686 0.8×	469 1.0×	167 0.5×	226 0.7×	13	2.3k
Jennifer L. Stamos United States	14	2.2k 1.2×	788 0.9×	210 0.4×	149 0.5×	566 1.8×	17	3.3k
Annalisa Petrelli Italy	19	1.4k 0.8×	490 0.6×	470 1.0×	175 0.5×	138 0.4×	26	2.1k
Stefan Hart Singapore	23	1.4k 0.8×	1.0k 1.2×	263 0.6×	221 0.7×	137 0.4×	30	2.7k
Saijun Fan United States	21	2.3k 1.3×	1.8k 2.2×	624 1.3×	205 0.6×	181 0.6×	41	3.4k
Gordon Alton United States	18	1.8k 1.0×	739 0.9×	221 0.5×	260 0.8×	390 1.2×	42	2.8k
Jenny Tan United States	20	1.3k 0.7×	648 0.8×	246 0.5×	340 1.0×	544 1.7×	46	2.5k
Fernando Vidal‐Vanaclocha Spain	34	1.6k 0.9×	965 1.2×	487 1.0×	942 2.9×	137 0.4×	72	3.1k
Karl‐Heinz Thierauch Germany	19	1.0k 0.6×	908 1.1×	409 0.9×	146 0.5×	156 0.5×	33	2.5k
Cinzia Lanzi Italy	33	1.5k 0.9×	895 1.1×	317 0.7×	167 0.5×	248 0.8×	73	2.4k

Countries citing papers authored by Richard Kendall

Since Specialization

Citations

This map shows the geographic impact of Richard Kendall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kendall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kendall more than expected).

Fields of papers citing papers by Richard Kendall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kendall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kendall. The network helps show where Richard Kendall may publish in the future.

Co-authorship network of co-authors of Richard Kendall

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Kendall. A scholar is included among the top collaborators of Richard Kendall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Kendall. Richard Kendall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hughes, Paul E., Karen Rex, Sean Caenepeel, et al.. (2016). In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Molecular Cancer Therapeutics. 15(7). 1568–1579. 44 indexed citations

Canon, Jude, Tao Osgood, Steven H. Olson, et al.. (2015). The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Molecular Cancer Therapeutics. 14(3). 649–658. 116 indexed citations

Harrington, Paul E., Kaustav Biswas, David J. Malwitz, et al.. (2014). Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. ACS Medicinal Chemistry Letters. 6(1). 68–72. 74 indexed citations

Payton, Marc, Dongyin Yu, Raffi Manoukian, et al.. (2014). Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method. Laboratory Investigation. 94(11). 1296–1308. 5 indexed citations

Juan, Gloria, Tammy L. Bush, Raffi Manoukian, et al.. (2014). AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. Journal of Translational Medicine. 12(1). 307–307. 10 indexed citations

Bush, Tammy L., Marc Payton, Scott Heller, et al.. (2013). AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models. Molecular Cancer Therapeutics. 12(11). 2356–2366. 44 indexed citations

Calzone, Frank J., Elaina Cajulis, Petia Mitchell, et al.. (2013). Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab. PLoS ONE. 8(2). e55135–e55135. 28 indexed citations

Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics. 9(8). 2399–2410. 58 indexed citations

Burgess, Teresa L., Jan Sun, Susanne Meyer, et al.. (2010). Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor. Molecular Cancer Therapeutics. 9(2). 400–409. 68 indexed citations

10.

Beltran, Pedro J., Petia Mitchell, Elaina Cajulis, et al.. (2009). AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics. 8(5). 1095–1105. 113 indexed citations

11.

Bilodeau, Mark T., Georgia B. McGaughey, Kathleen Coll, et al.. (2004). The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase. Bioorganic & Medicinal Chemistry Letters. 14(11). 2941–2945. 27 indexed citations

12.

Carnahan, Josette, Paul Wang, Richard Kendall, et al.. (2003). Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22. Clinical Cancer Research. 9(10). 5 indexed citations

13.

Bilodeau, Mark T., Kathleen Coll, William R. Huckle, et al.. (2003). Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. Bioorganic & Medicinal Chemistry Letters. 13(15). 2485–2488. 13 indexed citations

14.

Carnahan, Josette, Paul Wang, Richard Kendall, et al.. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.. PubMed. 9(10 Pt 2). 3982S–90S. 142 indexed citations

15.

Fraley, Mark E., William F. Hoffman, Robert S. Rubino, et al.. (2002). Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-a]pyrimidines: A New Class of KDR Kinase Inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(19). 2767–2770. 105 indexed citations

16.

Kendall, Richard, Ruth Z. Rutledge, Xianzhi Mao, et al.. (1999). Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues. Journal of Biological Chemistry. 274(10). 6453–6460. 99 indexed citations

17.

Goldman, Corey K., Richard Kendall, Gustavo Cabrera, et al.. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proceedings of the National Academy of Sciences. 95(15). 8795–8800. 365 indexed citations

18.

Murphy, Mark, et al.. (1997). Implementation of a Virtual Enterprise for Reservoir Management Applications. Proceedings of SPE Annual Technical Conference and Exhibition. 1 indexed citations

19.

Kendall, Richard, Guan Wang, & Kenneth A. Thomas. (1996). Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR. Biochemical and Biophysical Research Communications. 226(2). 324–328. 597 indexed citations breakdown →

20.

Broude, Norma, Richard Kendall, & Griselda Pollock. (1995). Dealing with Degas: Representations of Women and the Politics of Vision. Woman s Art Journal. 16(2). 35–35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact